Fidelity Investments’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Fidelity Investments’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-52	Closed	-$1.1K	–	5581
2023 Q2	$1.1K	Sell	52 -270	-84%	-$8.32K	﹤0.01%	4694
2023 Q1	$8.68K	Sell	322 -537	-63%	-$25K	﹤0.01%	4185
2022 Q4	$30.4K	Buy	859 +43	+5%	+$5.17K	﹤0.01%	3626
2022 Q3	$184K	Buy	816 +1	+0.1%	+$246	﹤0.01%	3071
2022 Q2	$154K	Buy	815 +802	+6,169%	+$162K	﹤0.01%	3201
2022 Q1	$3K	Buy	+13	New	+$2.06K	﹤0.01%	4608
2021 Q3	–	Sell	-6	Closed	-$1K	–	5185
2021 Q2	$1K	Buy	+6	New	+$1.5K	﹤0.01%	4134
2015 Q2	–	Sell	-736	Closed	-$6.28M	–	2825
2015 Q1	$6.28M	Buy	+736	New	+$6.43M	﹤0.01%	2155

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments's EIGR Position: Q3 2023 in Review

Fidelity Investments sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2023, closing a stake of 52 shares — an estimated $1.1K sold.

Fidelity Investments first reported a position in EIGR in Q1 2015 and held it in 8 quarters. The position peaked at $6.28M in Q1 2015. 51 funds tracked by Wall St. Rank hold EIGR as of Q3 2023.

Fidelity Investments reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
Fidelity Investments sold 52 Eiger BioPharmaceuticals, Inc. shares in Q3 2023, an estimated $1.1K.
Fidelity Investments first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2015 and held it in 8 quarters.
Fidelity Investments's Eiger BioPharmaceuticals, Inc. position peaked at $6.28M in Q1 2015.
51 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2023.

Based on Fidelity Investments's 13F filing for Q3 2023, filed 13 Nov 2023.